{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is ARCA biopharma, Inc. technically bullish or bearish?
As of June 13, 2025, the market trend is mildly bearish, indicated by daily moving averages and weekly Dow Theory, despite some mixed signals from MACD and RSI across different time frames.
Who are in the management team of ARCA biopharma, Inc.?
As of March 2022, the management team of ARCA biopharma, Inc. includes Robert Conway (Chairman), Dr. Michael Bristow (CEO), Dr. Linda Grais (Lead Independent Director), Dr. Anders Hove, Mr. Daniel Mitchell, and Dr. Raymond Woosley (Directors). They are responsible for the company's strategic direction and operations.
What does ARCA biopharma, Inc. do?
ARCA biopharma, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases, with a market cap of approximately $418.93 million and a recent net profit of -$21 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap.
How big is ARCA biopharma, Inc.?
As of Jun 18, ARCA biopharma, Inc. has a market capitalization of 418.93 million and reported net sales of 0.00 million with a net profit of -78.08 million over the last four quarters. Shareholder's funds were 382.22 million, and total assets amounted to 396.02 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
